What is Relmada Therapeutics, Inc.'s milestone payments?

Relmada Therapeutics, Inc. (RLMD) reported milestone payments of $500K in Q4 2025.

What does milestone payments mean?

Cash payments made to third parties upon the achievement of specific clinical, regulatory, or commercial development milestones. These payments are critical indicators of progress in R&D-heavy industries and represent significant capital commitments.

Relmada Therapeutics, Inc. RLMD Milestone Payments

Milestone Payments at other companies

InsmedINSM

$15M—

InsmedINSM

$15M—

Royalty PharmaRPRX

$50M0.0%

HRO

HarrowHROW

$1.75M—

Climb Bio, Inc.CLYM

$8M—

Tarsus Pharmaceuticals, Inc.TARS

$67.5M0.0%

Other financials

Income statement

See full

Operating income-$19.5M-6.8%

Net income-$19.1M-8.5%

EPS (diluted)-$0.22+62.1%

Balance sheet

See full

Cash & equivalents$9.8M+750%

Total debt$104.1M-40.4%

Total equity$218.7M+875%

Total assets$235.4M+750%

Cash flow

See full

Operating cash flow-$15.1M+16.6%

Valuation

See full

Market cap$677.17M+2,907%

Returns & leverage

See full

Return on equity-48.8%-20.0pp

Debt / equity0.9×0.0×

Current ratio18.3×+13.0×

Where this comes from

Reported directly by Relmada Therapeutics, Inc. in its filing.

Tagged under the XBRL concept rlmd:MilestonePayments.

The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Relmada Therapeutics, Inc.'s milestone payments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Relmada Therapeutics, Inc.'s milestone payments?: Relmada Therapeutics, Inc. (RLMD) reported milestone payments of $500K in Q4 2025.
What does milestone payments mean?: Cash payments made to third parties upon the achievement of specific clinical, regulatory, or commercial development milestones. These payments are critical indicators of progress in R&D-heavy industries and represent significant capital commitments.